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Abstract
Following infection, virulent mycobacteria persist and grow within the macrophage, suggest-
ing that the intrinsic activation of an innate antimicrobial response is subverted by the intra-
cellular pathogen. For Mycobacterium leprae, the intracellular bacterium that causes
leprosy, the addition of exogenous innate or adaptive immune ligands to the infected mono-
cytes/macrophages was required to detect a vitamin D-dependent antimicrobial activity. We
investigated whether there is an intrinsic immune response to M. leprae in macrophages
that is inhibited by the pathogen. Upon infection of monocytes with M. leprae, there was no
upregulation of CYP27B1 nor its enzymatic activity converting the inactive prohormone form
of vitamin D (25-hydroxyvitamin D) to the bioactive form (1,25α-dihydroxyvitamin D). Given
that M. leprae-induced type I interferon (IFN) inhibited monocyte activation, we blocked the
type I IFN receptor (IFNAR), revealing the intrinsic capacity of monocytes to recognize M.
leprae and upregulate CYP27B1. Consistent with these in vitro studies, an inverse relation-
ship between expression of CYP27B1 vs. type I IFN downstream gene OAS1 was detected
in leprosy patient lesions, leading us to study cytokine-derived macrophages (MΦ) to model
cellular responses at the site of disease. Infection of IL-15-derived MΦ, similar to MΦ in
lesions from the self-limited form of leprosy, with M. leprae did not inhibit induction of the
vitamin D antimicrobial pathway. In contrast, infection of IL-10-derived MΦ, similar to MΦ in
lesions from patients with the progressive form of leprosy, resulted in induction of type I IFN
and suppression of the vitamin D directed pathway. Importantly, blockade of the type I IFN
response in infected IL-10 MΦ decreased M. leprae viability. These results indicate that M.
leprae evades the intrinsic capacity of human monocytes/MΦ to activate the vitamin D-
mediated antimicrobial pathway via the induction of type I IFN.
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Author summary
Our macrophages are equipped with the ability to detect and kill invading pathogens, and
yet, these cells of the innate immune system are still subject to infection by intracellular
bacterium. In particular, mycobacterium, the type of intracellular bacteria responsible for
diseases such as tuberculosis and leprosy, are very successful at establishing infection
within macrophages. By studying Mycobacterium leprae, the etiological agent of leprosy,
we describe an immune evasion mechanism whereby this bacterial pathogen utilizes our
own antiviral immune response against the macrophage. Type I interferons (IFN) are a
major part of our immune response to viral infections; however, this response will also
suppress our ability to fight opportunistic bacterial infection. During infection of our
macrophages, M. leprae induces an aberrant type I IFN response that subsequently
suppresses our macrophage’s ability to activate the vitamin D-mediated antimicrobial
pathway, a critical antimicrobial response for containment of mycobacterium. Thus,
understanding how these pathogens can evade our immune response will be important
for the development of new therapies against these chronic infections.
Introduction
The ability of macrophages (MF) to kill intracellular pathogens is critical to the outcome of
infection. Addition of exogenous ligands derived from the pathogen such as a Toll-like recep-
tor 2 ligand (TLR2L) or from human immune cells, such as IFN-γ, provides an extrinsic signal
to activate a vitamin D-dependent antimicrobial activity against mycobacteria in infected MF
[1, 2]. In the absence of these exogenous stimuli, there is evidence for intrinsic antimicrobial
mechanisms, although these are not clearly defined nor sustained [3]. In this regard, microbial
pathogens have evolved mechanisms to evade these host defense pathways, establishing infec-
tion that results in clinical disease. Here we investigated whether in the absence of exogenous
triggers such as TLR2L or IFN-γ, there is intrinsic activation of a vitamin D-dependent antimi-
crobial pathway in infected human MF, as well as the presence of bacterial mechanisms of
escape, by studying leprosy as a disease model.
Leprosy, caused by the intracellular bacterium Mycobacterium leprae, presents as a spec-
trum of disease in which the clinical manifestation correlates with the immunological state of
the patient. At one end is the self-limiting tuberculoid form (T-lep) and the other end is the
disseminated lepromatous form (L-lep) [4], thus comparisons of each form of leprosy affords
the opportunity to uncover the critical intrinsic immune mechanisms needed to contain the
infection. Each pole of the leprosy disease spectrum is accompanied by a distinct immunologi-
cal profile defined by specific T cell subsets, MF populations and cytokine patterns [4]. Gene
expression profiling of skin lesions from patients with the different forms of leprosy suggested
a correlation between activation of the vitamin D pathway and favorable disease outcomes [5].
For over a century, the potential use of vitamin D as a treatment against pathogenic infec-
tions has been investigated [6–11]; however, only in recent years has the mechanisms by which
the immune system utilizes vitamin D to mount an antimicrobial response been described.
Human monocytes and MF can synthesize the active vitamin D hormone 1α,25-dihydroxyvi-
tamin D (1,25D) from the inactive prohormone substrate 25-hydroxyvitamin D (25D) upon
stimulation via innate or adaptive immune signals resulting in an antimicrobial response to
infection [1, 2, 12]. Conversion of 25D into 1,25D is mediated through the enzymatic actions
of 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1). Studies performed in vitro with human
MF have demonstrated that this vitamin D metabolic system plays a role in human MF
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antimicrobial activity against M. tuberculosis infection as well as in patients with tuberculosis
[1, 2, 5, 12, 13].
As the role of vitamin D in the human immune response against M. tuberculosis infection
becomes increasingly established, studies have also emerged linking these mechanistic findings
to other human mycobacterial diseases, in particular, leprosy [5, 14–17]. Expression of the vita-
min D pathway during disease may be an important facet to disease pathogenesis; therefore, it
is important to understand the factors that regulate the expression and function of this antimi-
crobial pathway. By comparing the gene expression profiles of lesions derived from T-lep vs.
L-lep patients, we were previously able to determine that M. leprae infection of human MF
resulted in the induction of type I IFN, which directly inhibited activation of the vitamin D-
dependent antimicrobial response triggered by exogenous addition of type II IFN (IFN-γ)
[17]. Here, we investigated whether the vitamin D antimicrobial pathway is intrinsically acti-
vated, in the absence of TLR2 and IFN-γ by M. leprae infection of MF, Furthermore, we evalu-
ated whether the ability of M. leprae to induce type I IFN blocks the intrinsic activation of the
vitamin D pathway, representing an escape mechanism by which the bacterium evades the
host response.
Materials and methods
Ethics statement
This study was conducted according to the principles expressed in the Declaration of Helsinki,
and was approved by the Institutional Review Board of the University of California at Los
Angeles. All donors provided written informed consent for the collection of peripheral blood
and subsequent analysis.
Statistics
Experiments comparing two conditions were analyzed using two tailed Student’s t-test. Multi-
ple condition experiments were analyzed using one-way ANOVA with pairwise analysis using
Newman-Keuls test. Other tests used are indicated in text. All data used to generate the figures
presented are available as S1 Data.
Immunohistochemistry
Skin biopsy specimens were collected from untreated patients at the Hansen’s Disease Clinic
at Los Angeles Country and University of Southern California Medical Center as well as the
Leprosy Clinic at the Oswaldo Cruz Foundation in Brazil. The diagnosis and classification of
patients were determined based on clinical and histopathological criteria of Ridley and Jopling
[4, 18]. Cryosections of skin lesions from T-lep, and L-lep patients were labeled for CYP27b1
(Santa Cruz Biotechnology, Dallas, TX). Sections were incubated with normal horse serum fol-
lowed by incubation with CYP27b1 antibody or matched isotype control for 60 minutes. Fol-
lowing primary antibody incubation, sections were incubated with biotinylated horse anti-
mouse IgG and visualized by ABC Elite system (Vector Laboratories) and AEC Peroxidase
Substrate Kit (Vector Laboratories). The section was then counterstained with hematoxylin
and mounted with crystal mounting medium (Biomeda). Skin sections were examined using a
Leica microscope (Leica 2500). Expression of CYP27b1 in photomicrographs was quantified
using ImmunoRatio (http://153.1.200.58:8080/immunoratio/), an automated image analysis
application that calculates the percent diaminobenzidine (DAB)-stained nuclear area per total
area [17].
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Primary human monocytes
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll (GE Healthcare, Chi-
cago, IL) density gradient from whole blood obtained from healthy donors with informed con-
sent. Monocytes were enriched using plastic adherence in which PBMCs were cultured for two
hours in RPMI 1640 media (Invitrogen, Carlsbad, CA) with 1% FBS (Omega Scientific, Tar-
zana, CA) followed by washing [2, 12, 14]. Monocytes were cultured in RPMI media with 10%
FBS and treated with 100ng/mL Pam3CSK4 (TLR2L), or M. leprae (MOI 10, gift from J.L. Kra-
henbuhl) immediately following adherence. For blocking type I IFN signaling, monocytes or
macrophages were treated with 10μg/mL anti-IFNAR antibody (PBL, Piscataway, NJ).
High-performance liquid chromatography (HPLC)
Following treatments as indicated in the text, monocytes or MF were incubated with radiola-
beled 3[H]-25D3 (PerkinElmer, Waltham, MA) substrate for 5 hours in serum-free RPMI
media. [3H]-metabolites were purified using a C18 column and separated using a Zorbax-sil
column (Agilent, Santa Clara, CA). Radioactivity was measured in each sample by scintillation
counting. The amount of each metabolite present was quantified from counts per minute plot-
ted against elution profiles of standards for 25D3, 1,25D3, and 24,25D3 [12].
Quantitative polymerase chain reaction (qPCR)
Total RNA was harvested using TRIzol (Thermo Fisher Scientific, Waltham, MA) and cDNA
synthesized using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). mRNA
expression levels for CYP27B1, CYP24A1, VDR, CAMP, and IFNB were assessed using the
Taqman system and pre-verified primer and probe sets (Thermo Fisher Scientific). Relative
expression was quantified by comparing to the housekeeping gene 18S rRNA and using the
ΔΔCt method [12, 14]. OAS1 mRNA levels were assessed using the SYBR Green system (Bio-
Rad Laboratories, Irvine, CA) compared to the housekeeping gene 36B4 using the ΔΔCt
method. 36B4 primers were previously published [14], and OAS1 primers are as follows: for-
ward 5’-GAG ACC CAA AGG GTT GGA GG-3’, and reverse 5’- GGA TCG TCG GTC TCA
TCG TC-3’.
ELISA
Secreted IFN-β protein in the supernatant were measured using VeriKine Human Interferon-
Beta ELISA Kit (PBL Interferon Source) following the manufacturer’s protocols.
Microarray analysis
The microarray experiment was previously published [17]. Gene expression profiles of
mRNAs derived from skin biopsy specimens of 16 leprosy patients (T-lep, n = 10; L-lep, n = 6)
were determined using Affymetrix Human U133 Plus 2.0 microarrays and analyzed as previ-
ously described. The raw gene expression data analyzed in this study are available online
through the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) acces-
sion number GSE17763.
MF differentiation
MF were differentiated using our previously described rapid protocols; briefly, monocytes
were directly treated with 103 U/mL IL-4 (Peprotech, Rocky Hill, NJ), 10μg/mL IL-10 (R&D
Systems, Minneapolis, MN), or 200ng/mL IL-15 (R&D Systems) for 48 hours immediately
following plastic adherence [5, 12, 13]. Completion of MF differentiation was confirmed
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histologically. Vitamin D supplementation experiments were carried out in vitro by the addi-
tion of 25-hydroxyvitamin D3 (Enzo Life Sciences, Farmingdale, NY) to the extracellular
medium of MF cultures.
M. leprae infection
MF were infected with single cell suspensions of M. leprae at MOI of 10 in antibiotic free
RPMI1640 supplemented with 10% FBS for 16 hours; then washed vigorously to remove extra-
cellular bacterium and cultured in RPMI 1640 supplemented with 10% FBS, penicillin and
streptomycin.
Antimicrobial assay
MF were infected with M. leprae as indicated above. Following washing the infected MF were
cultured with 10% 25D sufficient human serum. Total RNA and DNA were harvested from M.
leprae-infected macrophages as indicated in the text and cDNA was synthesized from the RNA
fraction. Bacterial 16S rRNA and M. leprae repetitive genomic element DNA (RLEP) were
measured using quantitative PCR. Bacterial viability was calculated by comparing 16S rRNA
to RLEP DNA as previously published [14].
Results
Our previous study indicated that components of the vitamin D-mediated antimicrobial path-
way, including CYP27B1 mRNA, were more highly expressed in T-lep lesions as compared to
L-lep lesions [5]. Examining the distribution of CYP27B1 protein in leprosy lesions by immu-
nohistochemistry, we observed greater expression of the enzyme throughout the granulomas
in the T-lep vs. L-lep form (Fig 1A), correlating with mRNA levels [5]. Quantification of pro-
tein expression levels in the leprosy lesions indicated that there were 3-fold higher number of
CYP27B1 positive cells in the T-lep vs. L-lep lesions (Fig 1B).
Given that M. leprae bacilli are more abundant in L-lep lesions, we determined the effect of
M. leprae on CYP27B1 expression and function. Cultures of primary human monocytes were
infected overnight with live M. leprae at a multiplicity of infection (MOI) of 10. Following
infection of monocytes, total RNA was isolated, then CYP27B1 mRNA expression was assessed
by qPCR. M. leprae infection did not significantly induce CYP27B1 mRNA expression in
monocytes, whereas stimulation with exogenous Toll-like receptor 2/1 ligand (TLR2L) did
(Fig 1C). Given that the function of CYP27B1 is to metabolize 25D into 1,25D, we cultured
TLR2L activated or M. leprae-infected monocytes with 25D3 for 6 hours, and the levels of
25D3, 1,25D3 and 24,25D3 were measured using high performance liquid chromatography
(HPLC). While monocytes treated with the exogenous TLR2L were able to significantly con-
vert 25D3 into 1,25D3, consistent with previous studies [2], M. leprae-infected monocytes did
not (Fig 1D). Conversely, gene expression of CYP24A1 mRNA, the enzyme that catalyzes 25D
into the non-VDR-interacting 25D catabolite, 24,25D, was significantly reduced by M. leprae
infection and TLR2L (Fig 1E). The reduction in CYP24A1 mRNA expression did not result in
a detectable change in enzymatic activity (Fig 1F). These results suggest that although M. leprae
expresses a cell wall associated lipoprotein capable of activating TLR2 [19], it does not activate
a monocyte intrinsic pathway leading to the induction of CYP27B1 without exogenous TLR2L
or IFN-γ.
Given our previous studies demonstrating that M. leprae induces monocytes to release a
broad array of cytokines [14, 17], we hypothesized that induction of specific cytokines downre-
gulates CYP27B1 expression. Of the known cytokines triggered in monocytes and MF during
M. leprae infection, IFN-β [17] has been shown to downregulate host immune responses [17].
Intrinsic immune response inhibited during M. leprae infection
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In particular, IFN-β inhibits IFN-γ induced CYP27B1 expression in M. leprae infected cells
[20, 21]. We therefore hypothesized that M. leprae induction of type I IFN inhibits the intrinsic
upregulation of CYP27B1 in the infected cells. Mining unpublished data from our previous
study [17], M. leprae infection significantly induced mRNA expression of IFN-β and IFN-β
protein; however, TLR2L had no effect (Fig 2A). In new experiments, M. leprae-infected
monocytes also significantly expressed type I IFN downstream gene product, OAS1 by qPCR,
indicating the presence of a type I IFN response (Fig 2B). Addition of a neutralizing monoclo-
nal antibody against the type I IFN receptor (IFNAR) to the monocyte cultures prior to M.
leprae infection inhibited OAS1 expression (Fig 2C), confirming activation of the type I IFN
pathway during M. leprae infection. In the same experiments, neutralization of IFNAR during
M. leprae infection resulted in a significant induction of CYP27B1 and VDR gene expression
Fig 1. CYP27B1 expression in leprosy and during M. leprae infection of primary human monocytes. (A) One representative labeled
section displaying CYP27b1 protein detection in leprosy lesions from one patient, (patient, n = 3), scale bar = 40 μm. Original
magnification: x100. (B) Automated image analysis of CYP27b1 protein expression. Each dot represents the percentage of CYP27b1–
stained area per nuclear area for each individual photomicrograph (n = 3 for each group). Data represent mean ± SEM. Statistical
significance was determined using student t-test. Primary human monocytes were treated with M. leprae at a multiplicity of infection
(MOI) of 10 or 100ng/mL Pam3CSK4 (TLR2L) for 24 hours and (C) CYP27B1 and gene expression levels were determined by
quantitative PCR, or the cells were incubated with radiolabeled 25D3 for 5 hours, and (D) conversion to 1,25D3 was measured by high
performance liquid chromatography (HPLC). Gene expression of (E) CYP24A1 and (F) conversion of 25D3 into 24,25D3 were also
measured. Data are shown as mean ± SEM, n>3. Statistical significance was determined using one-way ANOVA. ( p 0.05,
p 0.01, p 0.001).
https://doi.org/10.1371/journal.pntd.0006815.g001
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Fig 2. Blocking type I IFN signal during M. leprae infection relieves repression of intrinsic induction of CYP27B1.
(A) Primary human monocytes were infected with live M. leprae at MOI of 10 for 6 hours for mRNA and 24 hours for
culture supernatants. Interferon beta 1 (IFN-β) expression was measured using quantitative PCR and protein levels
measured using ELISA [17]. qPCR data are shown as mean fold change vs. media ± SEM, n = 5, and ELISA are shown
as mean concentration ± SEM, n = 5. (B) Primary human monocytes were infected with M. leprae at MOI of 10 for 24
Intrinsic immune response inhibited during M. leprae infection
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(Fig 2D), suggesting that M. leprae induction of type I IFN blocks activation of an intrinsic
response leading to upregulation of CYP27B1.
Monocytes are initially recruited to the site of infection where they encounter microbial
pathogens, but over time develop into tissue MF that contribute to outcome of the infection.
In leprosy, T-lep lesions are characterized by M1-like MF and a vitamin D antimicrobial
gene program; whereas, in L-lep lesions, M2-like MF predominate. To further explore the
relationship between MF, the vitamin D antimicrobial and type I IFN pathways, we interro-
gated our previously published microarray study [17]. CYP27B1 expression was significantly
greater in T-lep vs. L-lep lesions, and in 9/10 T-lep lesions greater than any of the six L-lep
lesions (Fig 3A). Conversely, CD163, a marker of the M2-like MF in L-lep lesions, was sig-
nificantly greater in L-lep vs. T-lep lesions, with the expression in 5/6 L-lep lesions greater
than any of the T-lep lesions (Fig 3A). Given that IFN-β, a type I IFN, protein and mRNA are
differentially expressed in L-lep vs. T-lep lesions, and impacts MF function [17], we exam-
ined mRNA levels for OAS1, which was significantly higher in L-lep lesions (Fig 3B). Linear
regression analysis indicates that CD163 and OAS1 expression are coordinately expressed
(P = 0.0004, R2 = 0.6019) and two way ANOVA analysis confirms that leprosy type of the
lesion is significantly (P = 0.0003) associated with differential gene expression of CYP27B1,
CD163 and OAS1 (Fig 3C).
To model the MF subtypes in leprosy lesions, we studied MF subsets derived in vitro with
IL-15- vs. IL-10-treated monocytes yielding M1-like vs. M2-like MF, respectively. We previ-
ously described the IL-15- vs. IL-10-derived MF, to be phenotypically similar and functionally
consistent with MF subtypes found in leprosy lesions [5, 13, 22]. We differentiated MF by
treating monocytes with IL-10 or IL-15 for 48 hours, then determined their ability to metabo-
lize vitamin D using HPLC as we have described above. Consistent with previous findings [5],
IL-15 MF, but not IL-10 MF converted 25D3 to 1,25D3 (Fig 3D), which correlates with our in
situ microarray and protein studies. To ascertain the effects of M. leprae infection on the vita-
min D metabolic system in MF, we infected IL-10 MF and IL-15 MF with M. leprae, and
measured CYP27B1and OAS1 mRNA expression by qPCR. M. leprae infection of IL-10 MF
did not alter CYP27B1 mRNA expression, although exogenous TLR2 stimulation induced a
significant upregulation (Fig 4A). On the other hand, CYP27B1 gene expression in IL-15 MF,
which have high CYP27B1 gene expression at baseline, was not significantly affected as a result
of either infection or stimulation with exogenous TLR2L (Fig 4A). In the same experiments,
M. leprae infection of IL-10 MF led to the significant induction of OAS1 gene expression, but
not stimulation with exogenous TLR2L (Fig 4B). In contrast, neither M. leprae infection not
TLR2/1 activation of IL-15 MF induced upregulation OAS1 as a result of infection or follow-
ing TLR2/1 stimulation. These findings suggest that in distinct MF subsets differentially regu-
late the vitamin D and type I IFN pathways.
To determine whether the vitamin D antimicrobial pathway was functional in M. leprae
infected IL-15 MF, we added 25D3 to infected cells and measured the vitamin D-dependent
antimicrobial peptide, cathelicidin (CAMP). Indeed, when exogenous 25D3 was added to M.
leprae infected IL-15 MF at various doses, CAMP gene expression was induced in a dose-
hours, and OAS1 gene expression was measured by qPCR. Data are shown as mean fold change vs. media ± SEM,
n = 4. (C) Primary human monocytes were pre-treated with a monoclonal neutralizing antibody against the type I IFN
receptor (IFNAR) or isotype control then infected with M. leprae for 24 hours. OAS1 gene expression was determined
by qPCR and represented as percent inhibition. Data are shown as mean ± SEM, n = 8. (D) Monocytes were pretreated
with IFNAR neutralizing antibody or isotype control then infected with M. leprae at MOI of 10 for 24 hours, then
CYP27B1 and VDR gene expression levels were measured using quantitative PCR. Data are shown as mean ± SEM,
n = 8. Statistical significance was determined using one-way ANOVA. (p 0.05, p 0.01, p 0.001).
https://doi.org/10.1371/journal.pntd.0006815.g002
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dependent fashion (Fig 4C), suggesting that these M1-like MF retain the intrinsic ability to
engage the vitamin D-dependent antimicrobial pathway during M. leprae infection in the pres-
ence of sufficient 25D3 prohormone.
The induction of the type I IFN response by M. leprae in infected IL-10 MF but not IL-15
MF, led us to explore the functional consequences of this cytokine response on the intrinsic
induction of the vitamin D antimicrobial pathway. IL-10 MF were treated with a neutralizing
monoclonal antibody specific for IFNAR and then infected with live M. leprae. The addition of
neutralizing IFNAR antibody restored an intrinsic activation pathway leading to upregulation
of CYP27B1 and VDR mRNA (Fig 5A), but conversely, inhibited expression of the type I IFN
downstream gene OAS1 (Fig 5B). These data indicate that intrinsic activation of the vitamin
Fig 3. CYP27B1 gene expression is negatively correlated with OAS1 gene expression in in vitro studies and in leprosy
lesions. (A) Correlation of CYP27B1 and CD163 as well as (B) OAS1 gene expression from microarray analysis of T-lep
(n = 6) and L-lep (n = 5) human skin lesions. (C) Radar plot of CYP27B1, CD163 and OAS1 expression in T-lep and L-lep
lesions normalized to the highest value in the experiment. (D) Primary human monocytes were treated with 10μg/mL IL-10
or 200ng/mL IL-15 for 48 hours. Control (Ctrl) MF were derived by treating monocytes with 103 U/mL IL-4 for 48 hours.
IL-10 MF and IL-15 MF were incubated with radiolabeled 25D3 for 5 hours and conversion of 25D3 to 1,25D3 was measured
by HPLC. Data are shown as mean ± SEM, n = 3. Statistical significance was determined using one-way ANOVA.
(p 0.01, p 0.001).
https://doi.org/10.1371/journal.pntd.0006815.g003
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D-dependent antimicrobial pathway during M. leprae infection is inhibited by the ability of
the bacteria to induce type I IFN. Finally, we addressed whether the induction of type I IFN by
M. leprae regulated an intrinsic antimicrobial response against M. leprae. In M. leprae-infected
IL-10 MF cultured with 25D-sufficient human serum (44 ng/ml of 25D), treatment with the
IFNAR neutralizing monoclonal antibody significantly reduced M. leprae viability as com-
pared to the isotype control (Fig 5C). These results suggest that M. leprae, upon infection of
M2-like MF, evades activation of the intrinsic antimicrobial response by invoking the type I
IFN pathway. In summary, the regulation of the vitamin D antimicrobial pathway in M1-like
vs. M2-like MF is distinct, and contributes to the outcome of the innate immune response to
M. leprae.
Discussion
Cells of the monocyte/MF lineage mount an innate antimicrobial response to defend against
infection by an intracellular pathogen, yet the microbe has evolved to counter this intrinsic
capacity to kill the foreign invader. Although the exogenous addition of purified ligands
(TLR2L) derived from the pathogen provides an extrinsic mechanism to activate a vitamin D-
dependent antimicrobial response in infected MF, the intrinsic activation of innate antimicro-
bial responses by the pathogen is not sustained [3]. Here we studied leprosy as a model to
ascertain whether MF are capable of an intrinsic antimicrobial response to infection by M.
leprae. We provide evidence here that infection of human MF by M. leprae intrinsically acti-
vates the vitamin D antimicrobial pathway as part of the innate immune response, but the bac-
terium blocks this response via the induction of type I IFN.
There is evidence for the existence of intrinsic anti-mycobacterial responses, although these
are not usually sustained, and escaping the initial antimicrobial response is key for the patho-
gen to establish long term infection [3]. The identification of distinct MF gene expression pro-
files induced according to virulence of the infecting strain of M. tuberculosis suggests that
Fig 4. IL-15 MF and IL-10 MF differentially respond to M. leprae infection. IL-15 MF and IL-10 MF were infected with M. leprae or stimulated
with TLR2L for 24 hours. (A) CYP27B1 and (B) OAS1 gene expression levels were assayed by quantitative PCR. (C) IL-15 MF were infected with M.
leprae and supplemented with 20nM 25D3, 100nM 25D3, or vehicle control for 24 hours. Cathelicidin (CAMP) gene expression was assayed by qPCR.
Data are shown as mean fold change ± SEM, n = 3. Statistical significance was determined using one-way ANOVA. (p 0.05, p 0.01,
p 0.001).
https://doi.org/10.1371/journal.pntd.0006815.g004
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subversion of the initial host response is critical to establishing infection [23]. Therefore, the
ability of the invading pathogen to modulate the intrinsic macrophage response, such as antag-
onizing TLR2 [24] or suppressing the vitamin D-dependent antimicrobial response, will lead
to immunopathology. Here, we demonstrate that monocytes and MF have the capacity to trig-
ger an intrinsic antimicrobial response during M. leprae infection in the absence of exogenous
triggers (TLR2L or IFN-γ), which is inhibited by the aberrant infection-induced expression of
type I IFN. M. leprae may activate the intrinsic immune response in MF through a variety of
pattern recognition receptors including TLR4, TLR9 and NOD2, but most importantly, TLR2
Fig 5. Blocking type I IFN signaling during M. leprae infection of IL-10 MF reduces bacterial viability. IL-10 MF
were pre-treated with either antibody against the type I IFN receptor, IFNAR, or isotype control then infected with M.
leprae at an MOI of 10 for 24 hours. (A) CYP27B1, VDR, and (B) OAS1 gene expression levels were measured using
qPCR. Data are shown as mean ± SEM, n< 5. (C) IL-10 MF were infected with M. leprae and co-treated with IFNAR
neutralizing monoclonal antibody, or isotype control for 5 days under vitamin D-sufficient conditions. The ratio of M.
leprae 16S RNA to RLEP DNA was calculated as a measurement of bacterial viability. Statistical significance was
determined using one-way ANOVA. (p 0.05, p 0.01).
https://doi.org/10.1371/journal.pntd.0006815.g005
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via the 19kDa [19], 33kDa [19, 25] and mLEP major membrane protein-II lipoproteins [26],
since TLR2 activation leads to induction of CYP27B1 expression [2].
The intrinsic activation of the vitamin D antimicrobial pathway requires the metabolic con-
version by the CYP27B1 enzyme of 25D, the inactive circulating prohormone (25D) and
requires into the bioactive form (1,25D3) to transactivate its cognate receptor, the vitamin D
receptor (VDR). Activation of human monocytes and MF by exogenous innate and adaptive
immune signals (such as TLR2/1 and IFN-γ, respectively) have been shown to induce expres-
sion and function of CYP27B1 [1, 2]. Our data demonstrate that in contrast to activation with
exogenously added TLR2 ligand or IFN-γ, monocytes infected with live M. leprae showed little
intrinsic induction of CYP27B1 expression or enzyme activity. When the type I IFN receptor
(IFNAR) was neutralized during M. leprae infection, the intrinsic induction of CYP27B1 dur-
ing M. leprae infection was uncovered. This suppression of CYP27B1 has in vivo relevance, as
we found that CYP27B1 is more highly expressed in T-lep vs. L-lep lesions, the self-limited vs.
progressive forms of leprosy, respectively, and was inversely correlated with type I IFN signal-
ing. Using our previously characterized and described in vitro models of the L-lep and T-lep
resident MF (M2-like IL-10 MF and M1-like IL-15 MF) [5], we demonstrated that M. leprae
infection of IL-10 MF induces a type I IFN response that inhibits CYP27B1 expression, similar
to observations in monocytes. In contrast, IL-15 MF maintain their CYP27B1 expression and
function in the presence of M. leprae infection. These data indicate that the regulation of
CYP27B1 in infected MF at the site of disease is critical to activation of the intrinsic antimicro-
bial response.
The induction of type I IFN is a well-studied host defense mechanism against viral infec-
tion; however, their role in the immune response against intracellular infection with mycobac-
teria and bacteria is less defined [27]. While type I IFN are critical to clearance of viral
infections, the same type I IFN response mediates suppression of antibacterial responses, lead-
ing to secondary bacterial infections, such as Streptococcus pneumonia [28]. The fact that the
robust expression of type I IFN and downstream genes along with low CYP27B1 expression is
characteristic of L-lep lesions and vice versa in T-lep lesions [17], suggests that the ability of
type I IFN to inhibit CYP27B1 contributes to the outcome of the host response against myco-
bacteria in leprosy. Given that the neutralization of type I IFN uncovers the intrinsic induction
of CYP27B1 expression following M. leprae infection in vitro, the induction of type I IFN pro-
vides an escape mechanism by which the bacterium subverts the vitamin D-mediated antibac-
terial response. The ability of type I IFN to inhibit CYP27B1 expression is likely related to the
production of the immunosuppressive cytokine IL-10, which has been shown to be induced by
type I IFN during M. leprae infection and inhibit CYP27B1 expression [14, 17]. Alternatively,
the CYP27B1 promoter region contains an IRF8 (-543) response element as determined by
MotifMap (http://motifmap.ics.uci.edu/), which is a type I IFN inducible transcription factor
with known gene suppression functions [29]. Other studies have suggested additional mecha-
nisms by which M. leprae blocks host defenses, some mediated through the mycobacterial cell
wall component phenolic glycolipid 1 (PGL-1). Several studies have shown that PGL-1 manip-
ulates host defense mechanisms such as complement activation, phagocytosis as well as cyto-
kine release to inhibit maturation of dendritic cells and modulate T cell responses [30–33]; all
of which enables survival of the bacteria. With regard to vitamin D-mediated antibacterial
responses, our previous study showed that microRNA-21 (hsa-miR-21) was highly expressed
in L-lep lesions vs. T-lep lesions and inhibited CYP27B1 gene expression and function [14].
Similar to the results presented here, hsa-miR-21 induction was exclusive to live M. leprae
infection and not induced by purified TLR2 ligands [14]. Importantly, neutralization of the
type I IFN pathway in M. leprae infected IL-10 MF resulted in decreased bacterial viability
by uncovering the intrinsic vitamin D-mediated antimicrobial response. Indeed, further
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understanding of the pathways by which M. leprae initiates immune inhibitory mechanisms
such as induction of the type I IFN pathway will provide novel therapeutic targets for myco-
bacterial diseases.
There is a well characterized genetic and functional association of the vitamin D pathway
with leprosy. Single nucleotide polymorphisms in the VDR gene are associated with the differ-
ent forms of leprosy [15, 34], as is expression levels of the protein itself [35]. However, the use
of vitamin D to treat mycobacterial disease has been studied in clinical trials, which have
shown inconsistent benefits [6, 10, 11, 36–39]. Our findings suggest a possible explanation for
the varied outcomes. The efficacy of elevated systemic 25D levels in affecting local antimicro-
bial responses at the site of infection is predicated on the ability of the innate immune cells to
convert the circulating 25D to 1,25D at the site of infection. Thus, if the pathogen bearing MF,
such as those found in L-lep lesions, were unable to convert 25D, it would not be surprising to
see minimal therapeutic benefit following vitamin D supplementation. More broadly, our find-
ings suggest that the clinical management of mycobacterial disease using vitamin D supple-
mentation will require simultaneous management of the vitamin D metabolic system to
achieve therapeutic benefit. In conclusion, our results demonstrate that the intrinsic capacity
of cells to activate antimicrobial defense mechanisms as part of the innate response, versus the
ability of the pathogen to mask these responses, is a critical determinant of the outcome of
infection.
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